Skip to main content
SpringerLink
Log in

Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin)

An example of potential problems for extrapolation of active drug concentrations from in vitro studies

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Boyd MR, Paull KD (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91–109

    CAS  Google Scholar 

  2. Delaloge S, Yovine A, Taamma A, et al (2001) Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients: preliminary evidence of activity. J Clin Oncol 19:1248–1255

    CAS  PubMed  Google Scholar 

  3. Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG (2002) Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcoma: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 50:309–319

    Article  CAS  PubMed  Google Scholar 

  4. Rosing H, Hillebrand MJX, Jimeno JM, Gòmez A, Floriano P, Faircloth G, Henrar REC, Vermorken JB, Cvitkovic E, Bult A, Beijnen JH (1998) Quantitative determination of ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 33:1134–1140

    Article  CAS  PubMed  Google Scholar 

  5. Ryan DP, Supko JG, Eder JP, et al (2001) Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 7:231–242

    CAS  PubMed  Google Scholar 

  6. Taamma A, Misset JL, Riofrio M, et al (2001) Phase I and pharmacokinetic study of ecteinascidin 743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19:1256–1265

    CAS  PubMed  Google Scholar 

  7. van Kesteren C, Cvitkovic E, Taamma A, et al (2000) Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 6:4725–4732

    PubMed  Google Scholar 

  8. Weinstein JN, Myers TG, O’Connor PM, Friend SH, Fornace AJ Jr, et al (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343–349

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

    Gianluca Tognon, Roberta Frapolli, Marco Zaffaroni, Eugenio Erba, Massimo Zucchetti & Maurizio D’Incalci

  2. Pharma Mar USA, Inc., 320 Putnam Avenue, Cambridge, MA 02139-4616, USA

    Glynn T. Faircloth

Authors
  1. Gianluca Tognon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberta Frapolli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Zaffaroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eugenio Erba
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Massimo Zucchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Glynn T. Faircloth
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maurizio D’Incalci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurizio D’Incalci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tognon, G., Frapolli, R., Zaffaroni, M. et al. Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin). Cancer Chemother Pharmacol 53, 89–90 (2004). https://doi.org/10.1007/s00280-003-0704-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-003-0704-y

Keywords

Search

Navigation